GP IIb/IIIa receptor inhibitors are used together with other antiplatelet and anticoagulants, increasing the risk of bleeding. Major and minor bleeding contributes to the majority of adverse events ranging from 1 to 10%. Cardiovascular side effects such as hypotension and bradycardia were reported as well. Thrombocytopenia contributes to about 1 to 5% of adverse reactions.